• Search
  • Menu

Discovery Stems From Here   

Find your tools for building human cell-based models & screening assays

Featured Product

Microglia

Human iPSC-derived Microglia provide a reliable and consistent model that phenotypically recapitulates human microglia responses in vitro.

Featured Service

Cell Reprogramming

A complete suite of custom cell reprogramming and characterization services from dedicated specialists to generate iPSCs from human cells using cutting edge technologies.

Featured White Paper

Atrial Cardiomyocytes

Are you using non-human cell models for your cardiac research? Download our new white paper to find out why human iPSC-derived Atrial Cardiomyocytes could improve your data.

Welcome to Axol Bioscience

YOUR HUMAN CELL CULTURE SPECIALISTS

We provide highly validated human iPSC-derived cells and primary cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.

Products
Blog
Services
Application
Notes
Publications
Contact Us

Latest News

  • Axol Bioscience appoints Liam Taylor as Chief Executive Officer

    27 August 2020

    Cambridge, UK, 26 August 2020: Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potential of the team, and its iPSC (induced pluripotent stem cell) technologies, products and services.

  • Chief Operating Officer appointed at Axol Bioscience

    15 May 2019

    We are delighted to announce that Chris Kirton joins us as our Chief Operating Officer; a senior operations leader with over 15 years of drug development, commercial and operational management experience in both industry and academia. Chris joins us from a leading supplier in the biotech industry and takes up his leadership role at Axol, bringing with him his extensive operational experience at the highest levels, focusing Axol's position and supporting growth within the Human iPSC-Derived Stem Cell market.

  • Major success for MESO-BRAIN partners will lead to breakthrough technology for developing new brain models

    2 May 2019


  • Neuroimmunology Drug Development (NIDD) 2019

    27 March 2019

    ✓ Our Booth #760
    ✓ Our Workshop (find out more)
    ✓ Our Poster (find out more)

  • Axol Bioscience launch human iPSC-derived Microglia

    13 December 2018

    Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.